Cargando…

Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Enhances the Antitumor Efficacy of Radiofrequency Ablation

G47Δ is a triple-mutated oncolytic herpes simplex virus type 1 designed to induce antitumor immune responses efficiently. We examine the usefulness of G47Δ as a neoadjuvant therapy for radiofrequency ablation (RFA), a standard local treatment for certain cancers such as liver cancer, but remote recu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamada, Tomoharu, Tateishi, Ryosuke, Iwai, Miwako, Koike, Kazuhiko, Todo, Tomoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501409/ https://www.ncbi.nlm.nih.gov/pubmed/32995479 http://dx.doi.org/10.1016/j.omto.2020.08.010

Ejemplares similares

Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models
por: Inoue, Kosuke, et al.
Publicado: (2023)

Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors
por: Yamada, Tomoharu, et al.
Publicado: (2022)

Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma
por: Yajima, Shoh, et al.
Publicado: (2021)

Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation
por: Sugawara, Kotaro, et al.
Publicado: (2021)

Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer
por: Sugawara, Kotaro, et al.
Publicado: (2020)

Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis
por: Uchihashi, Toshihiro, et al.
Publicado: (2021)

Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12
por: Fukuhara, Hiroshi, et al.
Publicado: (2023)

Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma
por: Chalise, Lushun, et al.
Publicado: (2022)

Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
por: Todo, Tomoki, et al.
Publicado: (2022)

A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma
por: Todo, Tomoki, et al.
Publicado: (2022)

Triple‐mutated oncolytic herpes virus for treating both fast‐ and slow‐growing tumors
por: Fukuhara, Hiroshi, et al.
Publicado: (2021)

Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors
por: Shiina, Shuichiro, et al.
Publicado: (2012)

Surgical Resection or Radiofrequency Ablation for Small Hepatocellular Carcinoma
por: Kawaguchi, Yoshikuni, et al.
Publicado: (2023)

Infectious complications related to radiofrequency ablation of liver tumors: The role of antibiotics
por: Nakagomi, Ryo, et al.
Publicado: (2021)

Efficacy of a third-generation oncolytic herpes simplex virus in neuroendocrine tumor xenograft models
por: Matsushima, Hideyuki, et al.
Publicado: (2019)

Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta
por: Wang, Jiani, et al.
Publicado: (2014)

Frequency of and Predictive Factors for Vascular Invasion after Radiofrequency Ablation for Hepatocellular Carcinoma
por: Asaoka, Yoshinari, et al.
Publicado: (2014)

Third‐generation oncolytic herpes simplex virus inhibits the growth of liver tumors in mice
por: Nakatake, Richi, et al.
Publicado: (2018)

Frequency, Risk Factors and Survival Associated with an Intrasubsegmental Recurrence after Radiofrequency Ablation for Hepatocellular Carcinoma
por: Tateishi, Ryosuke, et al.
Publicado: (2013)

Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation
por: Uchino, Koji, et al.
Publicado: (2018)

Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models
por: Hatta, Masahiko, et al.
Publicado: (2022)

Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma
por: Wang, Jia-Ni, et al.
Publicado: (2011)

Designing herpes viruses as oncolytics
por: Peters, Cole, et al.
Publicado: (2015)

Oncolytic virus therapy: A new era of cancer treatment at dawn
por: Fukuhara, Hiroshi, et al.
Publicado: (2016)

Radiofrequency Ablation of Renal Tumors: Four-Year Follow-Up Results in 47 Patients
por: Kim, Soo Dong, et al.
Publicado: (2012)

Association between hospital volume and in‐hospital mortality following radiofrequency ablation for hepatocellular carcinoma
por: Sato, M., et al.
Publicado: (2017)

Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo
por: Yin, Lei, et al.
Publicado: (2017)

Oncolytic herpes simplex virus armed with a bacterial GBP1 degrader improves antitumor activity
por: Xie, Jun, et al.
Publicado: (2023)

A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma
por: Takaoka, Hiroo, et al.
Publicado: (2011)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

Proton Beam Therapy versus Radiofrequency Ablation for Patients with Treatment-Naïve Single Hepatocellular Carcinoma: A Propensity Score Analysis
por: Sekino, Yuta, et al.
Publicado: (2022)

Entry of Oncolytic Herpes Simplex Virus into Human Squamous Cell Carcinoma Cells by Ultrasound
por: Okunaga, Shusuke, et al.
Publicado: (2015)

Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts
por: Liu, Sisi, et al.
Publicado: (2020)

Genetically coating oncolytic herpes simplex virus with CD47 allows efficient systemic delivery and prolongs virus persistence at tumor site
por: Fu, Xinping, et al.
Publicado: (2018)

Interventional Oncolytic Immunotherapy with LTX-315 for Residual Tumor after Incomplete Radiofrequency Ablation of Liver Cancer
por: Zhou, Guanhui, et al.
Publicado: (2022)

Ex‐vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy
por: Rossi, Gemma, et al.
Publicado: (2022)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

The use of oncolytic virotherapy in the neoadjuvant setting
por: Thomas, Raquela J, et al.
Publicado: (2022)

Updates to the antitumor mechanism of oncolytic virus
por: Bai, Yang, et al.
Publicado: (2019)

Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response
por: Qi, Xiaoqiang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ios60lftgugcur9114kq9qri33